MarketCapExport financials
Praxis Precision Medicines (PRAX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Praxis Precision Medicines Balance Sheet 2025-2011 | PRAX
Brief balance sheet overview of Praxis Precision Medicines
This overview follows the five latest available annual observations between 2021 and 2025.
The asset base grew from $292.7 million to $937.9 million, or +220.4%. Average annual growth of roughly 33.8% was strong.
Growth in the asset base was not matched by liabilities: +220.4% versus +42.5%. The balance sheet moved in a more conservative direction.
Equity funds 93.6% of assets versus 85.7% initially. This creates a conservative balance sheet structure.
The cash share moved from 47.4% to 38.1%. A higher figure generally provides more room in an adverse scenario.
The accumulated result is -$1.1 billion and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Praxis Precision Medicines shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet Praxis Precision Medicines
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -214 M | -78.8 M | -58.1 M | -134 M | -296 M | -43.4 M | -18 M | - | - | - | - | - | - | - |
Long Term Debt |
- | 110 K | 1.37 M | 2.5 M | 3.5 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
110 K | 1.26 M | 1.13 M | 1 M | 810 K | 763 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 110 K | 2.53 M | 4.68 M | 3.5 M | - | 122 M | 55.7 M | - | - | - | - | - | - | - |
Total Current Liabilities |
59.8 M | 37.6 M | 15.7 M | 34.3 M | 38.4 M | 15.7 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
59.8 M | 37.7 M | 18.3 M | 39 M | 41.9 M | 15.7 M | 129 M | 60.9 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 1.39 M | 2.82 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.14 B | -837 M | -654 M | -531 M | -317 M | -150 M | -81 M | -41.4 M | - | - | - | - | - | - | - |
Total Assets |
938 M | 483 M | 87.9 M | 115 M | 293 M | 303 M | 47.7 M | 19.8 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
357 M | 215 M | 81.3 M | 61.6 M | 139 M | 297 M | 45.4 M | - | - | - | - | - | - | - | - |
Book Value |
878 M | 445 M | 69.7 M | 76.1 M | 251 M | 287 M | -81 M | -41 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
878 M | 445 M | 69.7 M | 76.1 M | 251 M | 287 M | -81 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Praxis Precision Medicines
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | 110 K | 436 K | 755 K | 1.07 M | 1.37 M | 1.66 M | 1.95 M | 2.22 M | 2.5 M | 2.76 M | 3.01 M | 3.26 M | 3.5 M | 3.73 M | 3.96 M | - | - | 198 K | - | - | 763 K | 763 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 110 K | 729 K | 1.34 M | 1.93 M | 2.53 M | 3.18 M | 3.44 M | 4 M | 4.68 M | 2.76 M | 3.01 M | 3.26 M | 3.5 M | 3.73 M | 3.96 M | - | - | 198 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
52.5 M | 49.1 M | 50.2 M | 59.8 M | 52.9 M | 48.6 M | 39.5 M | 37.7 M | 33.6 M | 22 M | 20.7 M | 18.3 M | 20 M | 27.9 M | 33.9 M | 39 M | 31.7 M | 41.5 M | 48.5 M | 41.9 M | 28.5 M | 19.7 M | 13.7 M | 15.7 M | 10.6 M | 15.7 M | 15.7 M | 7.58 M | 7.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 1.17 M | 1.18 M | 1.26 M | 1.39 M | 1.55 M | 2.04 M | 2.54 M | 2.82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.41 B | -1.32 B | -1.23 B | -1.14 B | -1.05 B | -977 M | -906 M | -837 M | -778 M | -726 M | -693 M | -654 M | -627 M | -602 M | -568 M | -531 M | -489 M | -446 M | -385 M | -317 M | -258 M | -213 M | -177 M | -150 M | -123 M | -150 M | -150 M | -81 M | -81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.31 B | 1.39 B | 1.46 B | 938 M | 396 M | 453 M | 479 M | 483 M | 416 M | 441 M | 250 M | 87.9 M | 107 M | 133 M | 98.4 M | 115 M | 137 M | 180 M | 240 M | 293 M | 324 M | 354 M | 279 M | 303 M | 120 M | 303 M | 303 M | 47.7 M | 47.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
362 M | 475 M | 536 M | 358 M | 150 M | 158 M | 166 M | 216 M | 169 M | 146 M | 152 M | 81.7 M | 102 M | 125 M | 81.3 M | 62 M | 62.9 M | 56.5 M | 78.3 M | 140 M | 167 M | 177 M | 131 M | 297 M | 115 M | 297 M | 297 M | 44.8 M | 44.8 M | - | - | 18.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.26 B | 1.34 B | 1.41 B | 878 M | 344 M | 404 M | 439 M | 445 M | 383 M | 419 M | 230 M | 69.7 M | 86.8 M | 106 M | 64.5 M | 76.1 M | 105 M | 139 M | 191 M | 251 M | 296 M | 334 M | 266 M | 287 M | 109 M | 287 M | 287 M | 40.1 M | 40.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.26 B | 1.34 B | 1.41 B | 878 M | 344 M | 404 M | 439 M | 445 M | 383 M | 419 M | 230 M | 69.7 M | 86.8 M | 106 M | 64.5 M | 76.1 M | 105 M | 139 M | 191 M | 251 M | 296 M | 334 M | 266 M | 287 M | -123 M | 287 M | 287 M | -81 M | -81 M | -60.5 M | - | -41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Praxis Precision Medicines, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
Russia